BBBegoña Campos Balea

Begoña Campos Balea

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Begoña Campos Balea has a total of 184 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prognostic value of risk-stage classification in patients with stage III melanoma: results from the real-world GEM1801 Spanish registry

    by Pablo Cerezuela-Fuentes, Antonio Piñero-Madrona, José Luis Manzano, Miguel-Ángel Berciano-Guerrero, Pablo Ayala de Miguel, Eva Muñoz-Couselo, Teresa Puértolas, Carlos Aguado de la Rosa, Guillermo Crespo, Lorena Bellido, et al.

  • Open Access

    Real‐world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study

    by Miguel‐Ángel Berciano‐Guerrero, Elisabeth Pérez‐Ruiz, Ainara Soria, Javier Medina Martínez, Pablo Ayala de Miguel, Eva Muñoz‐Couselo, Lorena Bellido, Rafael López Castro, Enrique Espinosa, Lourdes Gutiérrez Sanz, et al.

    Background: Chemotherapy schemes have historically shown low efficacy in patients with metastatic melanoma and have been replaced by immunotherapy and targeted therapy. This work aimed to study whether chemotherapy remains an option after progression to immunotherapy in specific contexts. Methods: The GEM1801 registry includes patients with advanced melanoma in Spain. For this substudy, patients with metastatic melanoma who received chemotherapy after immunotherapy were selected. Baseline characteristics and treatment outcomes were analyzed. Results: Of the 1316 patients included, with a median time of 4.8 months (range, 0.0–35.8) from the first immunotherapy, 92 received chemotherapy: 12 after adjuvant immunotherapy (cohort A), 45 subsequently to immunotherapy (cohort B), and 35 after receiving bridge therapies (cohort C). The median age was 66 years (range, 35–94), and 55.4% of the patients were male. Most patients had an Eastern Cooperative Oncology Group (ECOG) status of ≤1 (65.2%), whereas only 21.7% had ECOG 2. Among the patients, 54.3% had elevated lactate dehydrogenase levels. Chemotherapy regimens received were taxane/platinum‐based therapies (47.8%), dimethyl triazeno imidazol carboxamide (DTIC) (26.1%), fotemustine (17.4%), and other alkylating agents such as temozolomide (8.7%). With a median follow‐up of 31.9 months, the objective response rate was 12%, the median progression‐free survival was 3.5 months (95% CI, 2.9–4.8), and the median overall survival was 6.1 months (95% CI, 5.3–9.2). Conclusions: As in previous studies, patients treated with chemotherapy after immunotherapy failure had poor outcomes, similar to those from pre‐immunotherapy era, and should be used when no other options are available.

  • Open Access

    Clinical outcomes and survival in patients with NSCLC and EGFR exon 20 mutations: evidence from real-world clinical practice in a retrospective study in Galicia

    by Begoña Campos Balea, Martín Emilio Lázaro Quintela, Ma Carmen Areses Manrique, Cristina Azpitarte Raposeiras, Jorge García-González, Francisco Javier Afonso Afonso, Manuel Fernández-Bruno, Natalia Fernández Núñez, Raquel Romero Van der Schoot, Lucía Santomé Couto

    Background: Non-small cell lung cancer (NSCLC) with mutations in epidermal growth factor receptor exon 20 (EGFR Ex20Ins) is rare and resistant to conventional tyrosine kinase inhibitors (TKIs), limiting treatment options. This retrospective study in Galicia (Spain) evaluated the clinical characteristics, treatment response, and survival of patients with NSCLC and EGFR Ex20Ins. Methods: Data from patients diagnosed between 2013 and 2023, confirmed by next-generation sequencing (NGS) or polymerase chain reaction (PCR), were included. Overall survival (OS), progression-free survival (PFS), and the incidence of serious adverse events were assessed. Results: Of the 43 patients in the present study, 39 had metastatic disease and were considered for survival analysis. Among patients with metastatic disease, the median OS was 14.6 months (95% CI: 7–20 months), and the median PFS was 7.4 months (95% CI: 3–12 months) with first-line therapy (1L). Patients treated with platinum-based chemotherapy in the 1L achieved a median PFS of 9.8 months (95% CI: 3–27 months), whereas those receiving TKIs achieved a median PFS of 3.4 months (95% CI: 1–12 months). No significant differences in treatment response were found according to age or sex. Conclusions: The results show the limited effectiveness of TKIs in patients with EGFR Ex20Ins and highlight the need for specific therapies. Platinum-based chemotherapy performed better in preventing disease relapse.

  • Open Access

    Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial

    by Mariano Provencio, Begoña Campos, María Guirado, Laia Vila, Rosario García Campelo, Miriam Dorta, Sergio Vázquez Estévez, Asia Ferrández, M. Ángeles Sala, Ana Laura Ortega, et al.

    Unresectable stage III NSCLC standard treatment is chemo-radiotherapy (CT-RT) followed by immunotherapy (IO) with durvalumab. We investigated adding an induction phase with chemo-immunotherapy (ChIO). APOLO was a multicentre, single-arm, phase 2 trial (NCT04776447). Non-resectable stage IIIA–IIIC NSCLC patients received induction ChIO (atezolizumab + carboplatin + paclitaxel, for 3 cycles), followed by concurrent CT-RT (3 cycles), and IO maintenance (atezolizumab for 16 cycles). Primary objective was 12-month progression-free survival (PFS). Secondary endpoints included 12- and 24-month overall survival (OS), ORR, first-site failure pattern, and safety. Exploratory endpoints included PD-L1, TMB, and ctDNA. 38 patients were enrolled. Median follow-up was 29.6 months (data cutoff, February 2024). PFS was 68.4% (95% CI, 51.1–80.7) at 12 months (statistically significant compared to null hypothesis of 55%) and 50.0% at 24 months; OS was 86.8% and 60.5%, respectively. After induction, 18 (47.4%) had partial response, 14 (36.8%) stable disease, and 5 (13.2%) progressive disease. Overall, 18 patients had disease progression: 8 local (44.4%) and 10 distant (55.6%). Grade ≥3 TRAEs occurred in 11 (28.9%) during induction, 10 (26.3%) during CT-RT, and 2 (5.3%) during maintenance. ChIO induction before CT-RT and IO maintenance showed activity and safety, warranting confirmation in larger studies.


  • Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study

    by Margarita Majem, Enric Carcereny, Bernard Doger, Tim Clay, Igor Bondarenko, Julio Peguero, Manuel Cobo, Martin Forster, Ewa Kalinka, Gema Maria Garcia Ledo, et al.

    PURPOSE: Eftilagimod alpha (efti), an antigen-presenting cell (APC) activator, may overcome PD-1/PD-L1 inhibitor primary resistance. This phase II study investigated efti plus pembrolizumab treatment in patients with first-line metastatic non–small cell lung cancer (NSCLC) unselected for PD-L1. METHODS: Patients, naïve to systemic therapy in the metastatic setting, received efti (30 mg subcutaneously every 2 weeks for eight 3-week cycles, then every 3 weeks up to 54 weeks) plus pembrolizumab (200 mg intravenously every 3 weeks for up to 105 weeks). The primary end point was objective response rate (ORR) by immune RECIST. Secondary end points included duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and tolerability. Exploratory end points included identification and characterization of biomarkers. PD-L1 tumor proportion score (TPS) was assessed centrally. RESULTS: In the intention-to-treat population (n = 114), the median age was 67 years (range, 44-85), 73.7% was male, and 62.3% had an Eastern Cooperative Oncology Group performance status score of 1. Most patients (77.8%) had low/negative (<50%) PD-L1 TPS. The unconfirmed ORR (iRECIST) was 40.4%, leading to a confirmed ORR of 35.1%. The median DoR was 21.6 months, the DCR was 72.8%, and the median PFS (iRECIST) was 6.6 months. The median OS was 20.2 months, with 44.7% patients alive at 24 months. Antitumor activity was seen across all PD-L1 levels. A low proportion of patients had treatment-related adverse events leading to permanent discontinuation (8.8%). CONCLUSION: The APC activator, efti, on top of pembrolizumab was well tolerated and showed encouraging antitumor activity in patients with first-line NSCLC irrespective of tumor PD-L1 expression.


  • Open Access

    SEOM-GEM clinical guidelines for cutaneous melanoma (2023)

    by Iván Márquez-Rodas, Eva Muñoz Couselo, Juan F. Rodríguez Moreno, Ana Mª Arance Fernández, Miguel Ángel Berciano Guerrero, Begoña Campos Balea, Luis de la Cruz Merino, Enrique Espinosa Arranz, Almudena García Castaño, Alfonso Berrocal Jaime

    Cutaneous melanoma incidence is rising. Early diagnosis and treatment administration are key for increasing the chances of survival. For patients with locoregional advanced melanoma that can be treated with complete resection, adjuvant—and more recently neoadjuvant—with targeted therapy—BRAF and MEK inhibitors—and immunotherapy—anti-PD-1-based therapies—offer opportunities to reduce the risk of relapse and distant metastases. For patients with advanced disease not amenable to radical treatment, these treatments offer an unprecedented increase in overall survival. A group of medical oncologists from the Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines, based on a thorough review of the best evidence available. The following guidelines try to cover all the aspects from the diagnosis—clinical, pathological, and molecular—staging, risk stratification, adjuvant therapy, advanced disease therapy, and survivor follow-up, including special situations, such as brain metastases, refractory disease, and treatment sequencing. We aim help clinicians in the decision-making process.


  • Open Access

    Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer

    by Mariano Provencio-Pulla, Diego Pérez-Parente, Sara Olson, Haroon Hasan, Begoña Campos Balea, Delvys Rodríguez-Abreu, Marta López-Brea Piqueras, Navdeep Pal, Samantha Wilkinson, Esther Vilas, et al.

    Introduction: Lung cancer is one of the most prevalent cancers and the leading cause of cancer death. Advanced non-small cell lung cancer (aNSCLC) patients frequently harbor mutations that impact their survival outcomes. There are limited data regarding the prognostic and predictive significance of these mutations on survival outcomes in the real-world setting. Methods: This observational retrospective study analyzed de-identified electronic medical records from the Flatiron Health Clinico-Genomic and FoundationCore® databases to identify patients with aNSCLC who initiated first-line immune checkpoint inhibitors (ICI; alone or in combination) or chemotherapy under routine care between 2016 and 2021. The primary objectives were to assess the prevalence of non-actionable mutations and to determine their association with overall survival (OS). Real-world progression-free survival (rwPFS) and real-world response (rwR) were investigated as secondary exploratory outcomes. Results: Based on an assessment of 185 non-actionable mutations in 2999 patients, the most prevalent mutations were TP53 (70%), KRAS (42%), CDKN2A/B (31%), and STK11 (21%). STK11, KEAP1, and CDKN2A/B mutations were significantly associated with lower rwR, shorter rwPFS and OS. KRAS mutations were clinically associated with shorter rwPFS in CIT-treated patients. Subgroup analysis revealed that fast progressors were significantly more likely to harbor STK11, KEAP1, and CDKN2A/B mutations. Accordingly, long-term survivors (LTS) showed a significantly lower prevalence of these mutations. Conclusion: Our results provide evidence on the prognostic value of STK11, KEAP1, and CDKN2A/B mutations in patients with aNSCLC. Further research is required to better understand the implications of these findings on patient management and future trial design and treatment selection.


  • Open Access

    Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes

    by Remei Blanco, Manuel Dómine, José Luis González, Sami Loutfi, Jordi Alfaro, Juana Saldaña, Jaime Rubio, Begoña Campos, Julia Hidalgo, Andrés Barba, et al.


  • Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus

    by Begoña Campos-Balea, Ovidio Fernández-Calvo, Roberto García-Figueiras, Carlos Neira, Carmen Peña-Penabad, Carmela Rodríguez-López, Rocío Vílchez-Simo, María Quindós-Varela

    In spite of the good prognosis of patients with early-stage melanoma, there is a substantial proportion of them that develop local or distant relapses. With the introduction of targeted and immune therapies for advanced melanoma, including at the adjuvant setting, early detection of recurrent melanoma and/or second primary lesions is crucial to improve clinical outcomes. However, there is a lack of universal guidelines regarding both frequency of surveillance visits and diagnostic imaging and/or laboratory evaluations. In this article, a multidisciplinary expert panel recommends, after careful review of relevant data in the field, a consensus- and experience-based follow-up strategy for melanoma patients, taking into account prognostic factors and biomarkers and the high-risk periods and patterns of recurrence in each (sub) stage of the disease. Apart from the surveillance intensity, healthcare professionals should focus on patients’ education to perform regular self-examinations of the skin and palpation of lymph nodes.


  • Open Access

    Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

    by Maria Gonzalez-Cao, Clara Mayo de Las Casas, Juana Oramas, Miguel A. Berciano-Guerrero, Luis de la Cruz, Pablo Cerezuela, Ana Arance, Eva Muñoz-Couselo, Enrique Espinosa, Teresa Puertolas, et al.

    Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an intermittent dosing of these drugs could delay the emergence of resistance. Contrary to expectations, the first published phase 2 randomized study comparing continuous versus intermittent schedule of dabrafenib (BRAFi) plus trametinib (MEKi) demonstrated a detrimental effect of the “on−off” schedule. Here we report confirmatory data from the Phase II randomized open-label clinical trial comparing the antitumoral activity of the standard schedule versus an intermittent combination of vemurafenib (BRAFi) plus cobimetinib (MEKi) in advanced BRAF mutant melanoma patients (NCT02583516). The trial did not meet its primary endpoint of progression free survival (PFS) improvement. Our results show that the antitumor activity of the experimental intermittent schedule of vemurafenib plus cobimetinib is not superior to the standard continuous schedule. Detection of BRAF mutation in cell free tumor DNA has prognostic value for survival and its dynamics has an excellent correlation with clinical response, but not with progression. NGS analysis demonstrated de novo mutations in resistant cases.